2012
P2‐412: A comparison of hippocampal atrophy algorithms to select outcome measures for clinical trials in mild‐to‐moderate Alzheimer's disease
Burns L, Rueckert D, Bhagwagar Z, Donohue M, Wolz R, Tiller J, Soares H, l'Italien G, Coric V, Hayes W, Fox N, Berman R. P2‐412: A comparison of hippocampal atrophy algorithms to select outcome measures for clinical trials in mild‐to‐moderate Alzheimer's disease. Alzheimer's & Dementia 2012, 8: p408-p408. DOI: 10.1016/j.jalz.2012.05.2037.Peer-Reviewed Original Research
2010
P1‐387: Mild to moderate Alzheimer's disease (AD) clinical trials: The role of hippocampal atrophy as an inclusion criterion
Risinger R, Berman R, Coric V, Han J, Kaplita S, Burns L, Bhagwagar Z, Hill D, Wolz R, Rueckert D, Feldman H. P1‐387: Mild to moderate Alzheimer's disease (AD) clinical trials: The role of hippocampal atrophy as an inclusion criterion. Alzheimer's & Dementia 2010, 6: s285-s286. DOI: 10.1016/j.jalz.2010.05.941.Peer-Reviewed Original Research
2001
Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low
Rabiner E, Bhagwagar Z, Gunn R, Sargent P, Bench C, Cowen P, Grasby P. Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low. American Journal Of Psychiatry 2001, 158: 2080-2082. PMID: 11729033, DOI: 10.1176/appi.ajp.158.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrainDepressive Disorder, MajorDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansMaleMiddle AgedPindololReceptors, SerotoninReceptors, Serotonin, 5-HT1Selective Serotonin Reuptake InhibitorsTomography, Emission-ComputedTreatment OutcomeConceptsPositron emission tomographyDose of pindololClinical trialsDepressed patientsSelective serotonin reuptake inhibitorsSignificant occupancyPresent clinical trialSerotonin reuptake inhibitorsPindolol augmentationAntidepressant medicationReuptake inhibitorsPET evidenceEmission tomographyPindololTrialsDoseAutoreceptorsMedicationsPatientsInconsistent resultsEfficacyVast majorityDoses